Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%
- Check21 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedMinor update: version bumped to v3.0.2; 'Back to Top' removed; no changes to essential content.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check50 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, as well as new content related to various biochemical compounds and proteins. Notably, azacitidine and entinostat have been removed, indicating a shift in focus or product offerings.SummaryDifference3%
- Check64 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.